By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Great Basin today announced it has filed for 510(k) clearance of its molecular diagnostic test for Clostridium difficile.

In addition to its application to the US Food and Drug Administration, the Salt Lake City firm said also that it plans to submit an application to the European Union by the end of the year to obtain CE marking for the test, and upon regulatory approvals in the US and Europe, the company will launch its assay and instrument immediately.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.